Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II randomized double-blind placebo-controlled study of HS-10380 in Chinese adults with schizophrenia
CTR20231835Phase 2Active
- Sponsor
- 江苏豪森药业集团有限公司；上海翰森生物医药科技有限公司/ 江苏豪森药业集团有限公司
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing HS-10380 with Placebo (2 arms). Started Sep 2023; status: active.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20231835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231835.